A phase III study of telaprevir in combination with VX 222, pegylated interferon alpha 2a, and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C, or patients who have relapsed after at least one course of treatment with pegylated interferon and ribavirin alone.
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Interferon alpha-2a; Lomibuvir; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- 07 Nov 2011 New trial record